C34
Conditions
Interventions
Group 1: - Patients with suspected lung cancer who have been referred to our clinic for further inpatient diagnostics
Day 1:
- Assessment of baseline data
- Evaluation of inclusion/exclusion criteria
Sponsors
Städtisches Klinikum Braunschweig gGmbH
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: • Patients with suspected lung cancer that were referred to our clinic for further in-hospital diagnostic procedures • Written informed consent • Age 18-90 years
Exclusion criteria
Exclusion criteria: • Previously established continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV)-Therapy • Previously established long term oxygen therapy (LTOT) • Evidence of a severely impaired left-ventricular ejection fraction (LVEF <40%) • Evidence of a severely impaired renal function (GFR <30ml/min) • Evidence of prior stroke or severe mental health dysfunction • Inability to tolerate sleep monitoring
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Impact of severe SDB (defined as apnoea and hypopnoea index (AHI) =30/h) versus no SDB (defines as AHI<5/h) on progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Impact of sleep quality markers on progression-free survival Impact of SDB severity, type and sleep quality markers markers on • Quality of life • Overall survival • Survival according to different therapeutic approaches (chemotherapy, radiochemotherapy, surgery) ? Tumor marker, gene mutation and immune marker expression • Survival according to different types of SDB • Objective cardiopulmonary exercise capacity (if feasible) Prevalence of SDB Symptoms of SDB in patients with lung cancer Objective clinical status | — |
Countries
Germany
Contacts
Public ContactThomas Bitter
Städtisches Klinikum Braunschweig gGmbH
Outcome results
None listed